Recent Posts
- Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method
- Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales
- Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio
- Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025
- Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29